CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5518.63M
Enterprise Value 3477.91M
Trailing P/E N/A
Forward P/E 1-5.21
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)578.19
Price/Book (mrq)3.58
Enterprise Value/Revenue 3532.78
Enterprise Value/EBITDA 6-7.88

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-37.85%
S&P500 52-Week Change 310.93%
52 Week High 328.81
52 Week Low 310.63
50-Day Moving Average 317.51
200-Day Moving Average 319.46

Share Statistics

Avg Vol (3 month) 3143.21k
Avg Vol (10 day) 3140.86k
Shares Outstanding 532.85M
Float 16.5M
% Held by Insiders 14.49%
% Held by Institutions 174.70%
Shares Short (May 14, 2020) 41.34M
Short Ratio (May 14, 2020) 46.63
Short % of Float (May 14, 2020) 45.62%
Short % of Shares Outstanding (May 14, 2020) 44.09%
Shares Short (prior month Apr. 14, 2020) 41.59M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-6,863.99%

Management Effectiveness

Return on Assets (ttm)-26.48%
Return on Equity (ttm)-45.06%

Income Statement

Revenue (ttm)897k
Revenue Per Share (ttm)0.04
Quarterly Revenue Growth (yoy)-80.70%
Gross Profit (ttm)-40.31M
EBITDA -60.65M
Net Income Avi to Common (ttm)-58.77M
Diluted EPS (ttm)-2.42
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)112.8M
Total Cash Per Share (mrq)3.43
Total Debt (mrq)5.4M
Total Debt/Equity (mrq)4.98
Current Ratio (mrq)10.89
Book Value Per Share (mrq)4.41

Cash Flow Statement

Operating Cash Flow (ttm)-51.85M
Levered Free Cash Flow (ttm)-30.9M